KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Change in Cash (2016 - 2025)

AbbVie (ABBV) has disclosed Change in Cash for 14 consecutive years, with -$400.0 million as the latest value for Q4 2025.

  • Quarterly Change in Cash rose 76.92% to -$400.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$295.0 million through Dec 2025, up 95.95% year-over-year, with the annual reading at -$295.0 million for FY2025, 95.95% up from the prior year.
  • Change in Cash for Q4 2025 was -$400.0 million at AbbVie, up from -$838.0 million in the prior quarter.
  • The five-year high for Change in Cash was $5.3 billion in Q1 2024, with the low at -$5.9 billion in Q3 2024.
  • Average Change in Cash over 5 years is -$161.0 million, with a median of -$436.5 million recorded in 2023.
  • The sharpest move saw Change in Cash tumbled 535.78% in 2021, then soared 310.96% in 2024.
  • Over 5 years, Change in Cash stood at -$2.4 billion in 2021, then decreased by 8.0% to -$2.6 billion in 2022, then soared by 82.02% to -$473.0 million in 2023, then crashed by 266.38% to -$1.7 billion in 2024, then surged by 76.92% to -$400.0 million in 2025.
  • According to Business Quant data, Change in Cash over the past three periods came in at -$400.0 million, -$838.0 million, and $1.3 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.